Mortality Risk Assessment in COVID-19 Venovenous Extracorporeal Membrane Oxygenation
Ghneim, Mira H
Kaczorowski, David J
Haase, Daniel J
Deatrick, Kristopher B
Rabinowitz, Ronald P
O'Connor, James V
Herr, Daniel L
Gammie, James S
Madathil, Ronson J
JournalAnnals of Thoracic Surgery
MetadataShow full item record
AbstractBackground: A life-threatening complication of coronavirus disease 2019 (COVID-19) is acute respiratory distress syndrome (ARDS) refractory to conventional management. Venovenous (VV) extracorporeal membrane oxygenation (ECMO) (VV-ECMO) is used to support patients with ARDS in whom conventional management fails. Scoring systems to predict mortality in VV-ECMO remain unvalidated in COVID-19 ARDS. This report describes a large single-center experience with VV-ECMO in COVID-19 and assesses the utility of standard risk calculators. Methods: A retrospective review of a prospective database of all patients with COVID-19 who underwent VV-ECMO cannulation between March 15 and June 27, 2020 at a single academic center was performed. Demographic, clinical, and ECMO characteristics were collected. The primary outcome was in-hospital mortality; survivor and nonsurvivor cohorts were compared by using univariate and bivariate analyses. Results: Forty patients who had COVID-19 and underwent ECMO were identified. Of the 33 patients (82.5%) in whom ECMO had been discontinued at the time of analysis, 18 patients (54.5%) survived to hospital discharge, and 15 (45.5%) died during ECMO. Nonsurvivors presented with a statistically significant higher Prediction of Survival on ECMO Therapy (PRESET)-Score (mean ± SD, 8.33 ± 0.8 vs 6.17 ± 1.8; P = .001). The PRESET score demonstrated accurate mortality prediction. All patients with a PRESET-Score of 6 or lowers survived, and a score of 7 or higher was associated with a dramatic increase in mortality. Conclusions: These results suggest that favorable outcomes are possible in patients with COVID-19 who undergo ECMO at high-volume centers. This study demonstrated an association between the PRESET-Score and survival in patients with COVID-19 who underwent VV-ECMO. Standard risk calculators may aid in appropriate selection of patients with COVID-19 ARDS for ECMO. © 2021
Rights/TermsCopyright © 2021. Published by Elsevier Inc.
Extracorporeal Membrane Oxygenation--mortality
Respiratory Distress Syndrome
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16319
- Risk Factors of Mortality for Patients Receiving Venovenous Extracorporeal Membrane Oxygenation for COVID-19 Acute Respiratory Distress Syndrome.
- Authors: Bergman ZR, Wothe JK, Alwan FS, Lofrano AE, Tointon KM, Doucette M, Bohman JK, Saavedra-Romero R, Prekker ME, Lusczek ER, Beilman G, Brunsvold ME
- Issue date: 2021 Dec
- Venovenous Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome in Adults: Prognostic Factors for Outcomes.
- Authors: Wu MY, Huang CC, Wu TI, Wang CL, Lin PJ
- Issue date: 2016 Feb
- Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis.
- Authors: Ramanathan K, Shekar K, Ling RR, Barbaro RP, Wong SN, Tan CS, Rochwerg B, Fernando SM, Takeda S, MacLaren G, Fan E, Brodie D
- Issue date: 2021 Jun 14
- Venovenous extracorporeal membrane oxygenation support in patients with COVID-19 respiratory failure: A multicenter study.
- Authors: Vigneshwar NG, Masood MF, Vasic I, Krause M, Bartels K, Lucas MT, Bronsert M, Selzman CH, Thompson S, Rove JY, Reece TB, Cleveland JC, Pal JD, Fullerton DA, Aftab M
- Issue date: 2022 Dec
- Analysis of COVID-19 Patients With Acute Respiratory Distress Syndrome Managed With Extracorporeal Membrane Oxygenation at US Academic Centers.
- Authors: Nguyen NT, Sullivan B, Sagebin F, Hohmann SF, Amin A, Nahmias J
- Issue date: 2021 Jul 1